Show simple item record

dc.contributor.authorThorsen, Arthur Sigird
dc.date.accessioned2014-03-04T18:20:47Z
dc.date.available2014-03-04T18:20:47Z
dc.date.issued2009-08
dc.identifier.otherthorsen_arthur_s_200908_ms
dc.identifier.urihttp://purl.galileo.usg.edu/uga_etd/thorsen_arthur_s_200908_ms
dc.identifier.urihttp://hdl.handle.net/10724/25965
dc.description.abstractThe Food and Drug Administration (FDA) mandates that prescription drug advertisements cannot be false or misleading in any particular, must reveal material facts about the product being promoted, including facts about the consequences that can result from use of the product as suggested in the promotional piece and should present information about effectiveness and information about risk in a balanced manner.4,11 This study evaluates the a sampling of the current broadcast Direct-to-Consumer Advertising with the newly released FDA guidance document titled Presenting Risk Information in Prescription Drug and Medical Device Promotion. DRAFT GUIDANCE May 2009. The fair balance presentation of risk and benefit information within a cross section of drug advertisements was examined during two national nightly network television news broadcasts from May 25, 2009 to June 25, 2009.
dc.languageeng
dc.publisheruga
dc.rightspublic
dc.subjectDirect-to-Consumer Advertising
dc.subjectPrescription drugs
dc.subjectPharmaceutical
dc.subjectRisk
dc.subjectBenefit
dc.subjectContraindications
dc.subjectSide effects.
dc.titleAnalysis of the risk and benefit information presented in broadcast direct-to-consumer advertising
dc.typeThesis
dc.description.degreeMS
dc.description.departmentBioPharma Regulatory Affairs
dc.description.majorPharmacy
dc.description.advisorRandall Tackett
dc.description.committeeRandall Tackett
dc.description.committeeDavid Mullis
dc.description.committeePaul Brooks


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record